CPC A61K 35/17 (2013.01) [A61K 35/768 (2013.01); A61K 38/1774 (2013.01); A61K 38/28 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C12N 7/00 (2013.01)] | 13 Claims |
1. A therapeutic agent for the treatment of tumors and/or cancers of a subject, comprising:
(a) a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide;
(b) a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro;
wherein the nucleic acid when administered to the patient as part of the first pharmaceutical composition causes the tumor cells and/or cancer cells of the patient to express immunogens that can elicit an immune response of the immune cells;
wherein the labelling polypeptide comprises three identical antigenic epitope peptides derived from a tumor-associated antigen of NY-ESO-1 157-165 (SEQ ID NO:2), and the immune cells comprise TCR-modified T cells that can specifically recognize and bind to the labelling polypeptide; and
wherein the first active ingredient is a recombinant oncolytic adenovirus capable of selectively replicating in tumor cells.
|